凌四海, 支杨, 李莹, 陈霞利, 刘辰庚. 血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值[J]. 疾病监测, 2022, 37(6): 821-825. DOI: 10.3784/jbjc.202201190005
引用本文: 凌四海, 支杨, 李莹, 陈霞利, 刘辰庚. 血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值[J]. 疾病监测, 2022, 37(6): 821-825. DOI: 10.3784/jbjc.202201190005
Ling Sihai, Zhi Yang, Li Ying, Chen Xiali, Liu Chengeng. Value of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 and microRNA-388-5p in early diagnosis of Alzheimer's disease[J]. Disease Surveillance, 2022, 37(6): 821-825. DOI: 10.3784/jbjc.202201190005
Citation: Ling Sihai, Zhi Yang, Li Ying, Chen Xiali, Liu Chengeng. Value of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 and microRNA-388-5p in early diagnosis of Alzheimer's disease[J]. Disease Surveillance, 2022, 37(6): 821-825. DOI: 10.3784/jbjc.202201190005

血浆NCAM/ABCA1双标外泌体内Aβ42和microRNA-388-5p在阿尔茨海默病早期诊断中的价值

Value of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 and microRNA-388-5p in early diagnosis of Alzheimer's disease

  • 摘要:
      目的  检测神经细胞黏附分子(NCAM)和三磷酸腺苷(ATP)结合盒转运体A1(ABCA1)双标记外泌体内Aβ42和microRNA-388-5p(miR-388-5p),并分析其在阿尔茨海默病(AD)早期诊断中的潜在价值。
      方法  检测67例主观认知下降(SCD)、65例遗忘型轻度认知障碍(aMCI)、68例痴呆期阿尔茨海默病(DAT)患者、60例健康对照组受试者及60例血管性痴呆(VaD)的疾病对照组患者的血浆NCAM/ABCA1外泌体Aβ42和miR-388-5p水平,分析各指标间的相关性及其对疾病发展阶段的诊断效能。
      结果  SCD、aMCI和DAT受试者血浆NCAM/ABCA1双标外泌体Aβ42水平均显著高于VaD和健康对照组受试者(P<0.05);SCD、aMCI和DAT受试者血浆NCAM/ABCA1双标外泌体miR-388-5p含量均显著低于VaD及对照组受试者(P<0.05)。 血浆NCAM/ABCA1双标外泌体内Aβ42对SCD、aMCI和DAT诊断的敏感度和特异度均高于miR-388-5p。
      结论  本研究提示NCAM/ABCA1双标外泌体中Aβ42和miR-388-5p可作为aMCI和SCD诊断或预警的候选标志物,但尚需纵向多中心研究以进一步证实。

     

    Abstract:
      Objective   To detect the dual-labeled Aβ42 and miR-388-5p in exosomes of nerve cell adhesion molecule (NCAM) and ATP binding cassette transporter A1 (ABCA1), and analyze their potential value in the early diagnosis of Alzheimer's disease (AD).
      Methods   The levels of plasma NCAM/ABCA1 exosomes Aβ42 and miR-388-5p of 67 cases of subjective cognitive decline (SCD), 65 cases of amnestic mild cognitive impairment (aMCI), 68 Alzheimer's disease cases with dementia (DAT), 60 healthy controls and 60 controls of vascular dementia (VaD) cases were detected, and the correlation between the indicators and the diagnostic power of each disease stage were analyzed.
      Results  The plasma levels of NCAM/ABCA1 double-labeled exosomes Aβ42 in SCD, aMCI and DAT cases were significantly higher than those in controls of VaD cases and healthy controls (P<0.05). In plasma NCAM/ABCA1 of SCD, aMCI and DAT cases, the content of miR-388-5p in double-labeled exosomes was significantly lower than those of controls of VaD cases and healthy controls (P<0.05). The sensitivity and specificity of plasma NCAM/ABCA1 double-labeled exosomal Aβ42 for SCD, aMCI and DAT were higher than those of miR-388-5p.
      Conclusion  This study suggests that Aβ42 and miR-388-5p in NCAM/ABCA1 double-labeled exosomes can be used as candidate markers for the diagnosis or early warning of aMCI and SCD, but longitudinal multicenter studies are still needed to further confirm the results.

     

/

返回文章
返回